WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Refugee agency chief warns that the number of Syrians leaving Lebanon is likely to rise
A Star in Her Own Right — Ye Shuhua Dedicates Life to Development of Nation, Astronomy
Niu Shuli Explores Nature with Love and Passion
'Puppet Sister' Creates 'Intelligent' Robot Performers
What's causing the catastrophic rainfall in Kenya?
Miao's History, Culture Shine at Xiangxi Miao Drum Dance
Uygur Woman Shows Charm of Xinjiang Through Fabulous Dance
Women can stand the cold BETTER than men, surprising study finds
'Puppet Sister' Creates 'Intelligent' Robot Performers